2 recruiting, 1 completed. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 1 | Completed 1 |
Follow Biossil Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype Senicapoc, Placebo - Sickle Cell Disease, Sickle Cell Anaemia | Phase 2 | Recruiting | Biossil Inc. | 105 | 2026-08-13 | 2026-08-17 |
| Senicapoc in Alzheimer's Disease Senicapoc, Placebo Tablet - Mild Cognitive Impairment, Alzheimer Disease | Phase 2 | Recruiting | University of California, Davis | 55 | 2022-03-18 | 2026-08-17 |
| Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease Rivipansel, Placebo - Anemia, Sickle Cell | Phase 3 | Completed | Biossil Inc. | 345 | 2015-06-17 | 2025-03-11 |
Anemia, Sickle Cell (2) · Alzheimer Disease (1) · Anemia (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Cognitive Dysfunction (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemoglobinopathies (1) · Vaso-Occlusive Crises (1)
senicapoc (2) · TRAM 34 (1) · rivipansel (1)
Canada (2) · United States (2)